Interim results from the randomized, 300-patient CLASP IID trial showed Edwards Lifesciences’ Pascal mitral valve transcatheter edge-to-edge repair (M-TEER) system matched the performance of Abbott’s MitraClip M-TEER system in the treatment of symptomatic mitral regurgitation (MR) in patients who could not withstand surgery.
Lead investigators Konstantinos Koulogiannis from Morristown Medical Center in New Jersey and Scott Lim from the University of Virginia presented the results on 17 September at the Transcatheter Cardiovascular Therapeutics (TCT) conference
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?